National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Cancer (15)
- Cancer: Colorectal Cancer (3)
- (-) Cancer: Prostate Cancer (20)
- Care Management (2)
- Colonoscopy (1)
- Comparative Effectiveness (2)
- Decision Making (1)
- Dementia (1)
- Diagnostic Safety and Quality (1)
- Disparities (1)
- Elderly (1)
- Evidence-Based Practice (4)
- Guidelines (3)
- Healthcare Costs (1)
- Healthcare Delivery (1)
- Healthcare Utilization (2)
- Health Information Technology (HIT) (1)
- Hospitals (1)
- Imaging (3)
- Medication (1)
- Men's Health (7)
- Mortality (2)
- Outcomes (3)
- Patient-Centered Outcomes Research (4)
- Practice Patterns (3)
- Prevention (1)
- Primary Care (1)
- Quality of Life (1)
- Racial and Ethnic Minorities (2)
- Registries (1)
- Risk (3)
- Screening (4)
- Sexual Health (1)
- Surgery (4)
- Treatments (2)
- U.S. Preventive Services Task Force (USPSTF) (2)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 20 of 20 Research Studies DisplayedChapman CH, Caram MEV, Radhakrishnan A
Association between PSA values and surveillance quality after prostate cancer surgery.
This study examined the association between PSA values and posttreatment surveillance after prostate cancer surgery. Normally the treatment cutoff rate is 0.2 ng/mL but 4.0 ng/mL may be more appropriate. Data from the US Veterans Health Administration was used to perform a retrospective longitudinal cohort study for men diagnosed with nonmetastatic prostate cancer from 2005 to 2008 who underwent radical prostatectomy. Guideline concordance was high at year 1 (95%) but decreased to 79% in year 7. After adjustment, guideline concordance was lowered for the youngest and oldest, Black, and unmarried men.
AHRQ-funded; HS018726.
Citation: Chapman CH, Caram MEV, Radhakrishnan A .
Association between PSA values and surveillance quality after prostate cancer surgery.
Cancer Med 2019 Dec;8(18):7903-12. doi: 10.1002/cam4.2663..
Keywords: Cancer: Prostate Cancer, Cancer, Surgery, Screening, Guidelines, Prevention, Evidence-Based Practice
Mullins BT, Basak R, Broughman JR
Patient-reported sexual quality of life after different types of radical prostatectomy and radiotherapy: analysis of a population-based prospective cohort.
This study compares the effects of different types of radical prostatectomy and radiotherapy on sexual function. A population-based cohort of 835 men with newly diagnosed prostate cancer from 2011 through 2013 was recruited in collaboration with the Rapid Case Ascertainment system of the North Carolina Central Cancer Registry. They were enrolled prior to treatment and followed retrospectively using the validated Prostate Cancer Symptom Indices (PCSI) instrument. The sexual function scores were compared among patients who received the following treatment types: external-beam RT (EBRT), EBRT with androgen deprivation therapy (ADT), brachytherapy, nerve-sparing radical prostatectomy (RP), and non-nerve-sparing RP. The cohort was surveyed at 24 months post-therapy, and RT alone was found to result in the best preservation of sexual function with brachytherapy, RT with ADT, and nerve-sparing RP yielding similar outcomes. Patients treated with non-nerve-sparing RP experienced the worst sexual function outcome.
AHRQ-funded.
Citation: Mullins BT, Basak R, Broughman JR .
Patient-reported sexual quality of life after different types of radical prostatectomy and radiotherapy: analysis of a population-based prospective cohort.
Cancer 2019 Oct 15;125(20):3657-65. doi: 10.1002/cncr.32288..
Keywords: Quality of Life, Sexual Health, Surgery, Treatments, Comparative Effectiveness, Patient-Centered Outcomes Research, Outcomes, Cancer: Prostate Cancer, Cancer, Evidence-Based Practice
Modi PK, Kaufman SR, Herrel LA
Practice-level adoption of conservative management for prostate cancer.
In this study, the authors describe the longitudinal adoption of conservative management (ie, the absence of treatment) for prostate cancer among urology group practices in the United States and identify group practice features that influence this adoption. The investigators found that there was increasing variation among group practices in the use of conservative management for prostate cancer. They indicated that this underscores the need for a better understanding of practice-level factors that influence prostate cancer management.
AHRQ-funded; HS025707.
Citation: Modi PK, Kaufman SR, Herrel LA .
Practice-level adoption of conservative management for prostate cancer.
J Oncol Pract 2019 Oct;15(10):e863-e69. doi: 10.1200/jop.19.00088.
.
.
Keywords: Cancer: Prostate Cancer, Cancer, Practice Patterns, Care Management
Caram MEV, Kaufman SR, Modi PK
Adoption of abiraterone and enzalutamide by urologists.
The purpose of this study was to investigate the adoption of abiraterone and enzalutamide by urologists. Abiraterone and enzalutamide are oral therapies approved for the treatment of metastatic castration-resistant prostate cancer, a disease most commonly treated by medical oncologists. The investigators found that urologists are increasingly prescribing oral therapies for metastatic castration-resistant prostate cancer. They suggest that understanding the distribution of urologists specializing in castration-resistant prostate cancer therapeutics will help guide future interventions to optimize the care for this important patient population.
AHRQ-funded; HS025707.
Citation: Caram MEV, Kaufman SR, Modi PK .
Adoption of abiraterone and enzalutamide by urologists.
Urology 2019 Sep;131:176-83. doi: 10.1016/j.urology.2019.05.012..
Keywords: Cancer, Cancer: Prostate Cancer, Care Management, Medication, Men's Health
Cedars B, Lisker S, Borno HT
An electronic registry to improve adherence to active surveillance monitoring among men with prostate cancer at a safety-net hospital: protocol for a pilot study.
The goal of this study was to assess the efficacy and feasibility of a health information technology registry for men on active surveillance at a safety-net hospital to ensure patients receive guideline-recommended care. Use of a customized electronic approach for monitoring men on active surveillance could improve patient outcomes. It may help reduce the number of men lost to follow-up and improve adherence to timely follow-up testing.
AHRQ-funded; HS023558.
Citation: Cedars B, Lisker S, Borno HT .
An electronic registry to improve adherence to active surveillance monitoring among men with prostate cancer at a safety-net hospital: protocol for a pilot study.
Pilot Feasibility Stud 2019 Aug 14;5:101. doi: 10.1186/s40814-019-0482-x..
Keywords: Cancer, Cancer: Prostate Cancer, Health Information Technology (HIT), Men's Health, Registries
Ankerst DP, Goros M, Tomlins SA
Incorporation of urinary prostate cancer antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.
The objective of this study was to determine whether the incorporation of two urinary markers, prostate cancer antigen 3 (PCA3) and TMPRSS2:ERG (T2:ERG), into the Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) tool improves its discrimination, accuracy, and clinical net benefit. A Bayesian modeling approach was used to combine data where the markers were measured in a Michigan cohort with the PCPTRC as prior probabilities to create an updated PCPTRC; this update was compared to the existing PCPTRC in terms of discrimination, calibration, and decision curve analysis. Net benefit was improved for the updated PCPTRC, but calibration was not. The authors note that, the updated PCPTRC is limited since it was based on two separate cohorts, and further validation is required. The updated tool is available online.
AHRQ-funded; HS024810.
Citation: Ankerst DP, Goros M, Tomlins SA .
Incorporation of urinary prostate cancer antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.
Eur Urol Focus 2019 Jan;5(1):54-61. doi: 10.1016/j.euf.2018.01.010..
Keywords: Cancer, Cancer: Prostate Cancer, Men's Health, Risk
Modi PK, Herrel LA, Kaufman SR
Urologist practice structure and spending for prostate cancer care.
This study examined the impact of urologist practice structure on health care spending for men being treated for prostate cancer. Their hypothesis that spending would be lower for urologists in multispecialty group practices and higher for practices with intensity-modulated radiation therapy (IMRT) ownership. A sample of 35.929 men with newly diagnosed prostate cancer being treated by 6381 urologists was identified. The sample came from fee-for-service Medicare beneficiaries between 2011 and 2014. Their hypothesis was proven true with the lowest costs for men going to MSGs and significantly higher among practices with IMRT ownership.
AHRQ-funded; HS025707.
Citation: Modi PK, Herrel LA, Kaufman SR .
Urologist practice structure and spending for prostate cancer care.
Urology 2019 Aug;130:65-71. doi: 10.1016/j.urology.2019.03.029.
.
.
Keywords: Cancer: Prostate Cancer, Cancer, Healthcare Costs, Men's Health
Jayadevappa R, Chhatre S, Malkowicz SB
Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer.
The purpose of this study was to analyze the association between androgen deprivation therapy (ADT) exposure and diagnosis of Alzheimer disease or dementia among elderly men with prostate cancer. Results showed that, among elderly patients with prostate cancer, ADT exposure was associated with subsequent diagnosis of Alzheimer disease or dementia over a follow-up period of at least 10 years.
AHRQ-funded; HS024106.
Citation: Jayadevappa R, Chhatre S, Malkowicz SB .
Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer.
JAMA Netw Open 2019 Jul 3;2(7):e196562. doi: 10.1001/jamanetworkopen.2019.6562..
Keywords: Cancer, Cancer: Prostate Cancer, Dementia, Elderly, Men's Health, Risk
Kirk PS, Borza T, Caram MEV
Characterising potential bone scan overuse amongst men treated with radical prostatectomy.
The authors characterized bone scan use after radical prostatectomy (RP) using data from a large, national integrated delivery system. They found a substantial rate of bone scan utilization after RP. The majority were performed for prostate-specific antigen levels in which the likelihood of a positive test was low. They recommended more judicious use of imaging in the post-RP setting.
AHRQ-funded; HS025707.
Citation: Kirk PS, Borza T, Caram MEV .
Characterising potential bone scan overuse amongst men treated with radical prostatectomy.
BJU Int 2019 Jul;124(1):55-61. doi: 10.1111/bju.14551..
Keywords: Cancer: Prostate Cancer, Cancer, Surgery, Imaging, Healthcare Utilization
Gordon BE, Basak R, Carpenter WR
Factors influencing prostate cancer treatment decisions for African American and white men.
This prospective, population-based cohort study examined some possible reasons for mortality outcome differences for prostate cancer between African American (AA) and white patients. A cohort of 1170 men with nonmetastatic prostate cancer were enrolled from 2011 to 2013 before treatment in North Carolina. Participants were asked to rate their aggressiveness of their cancer, and also the importance of 10 factors their treatment decision-making process. Among low-risk patients, there was no difference in perception of their cancer as “not very aggressive”. Among high-risk patients, 54% of AA patients considered their cancer to be “not very aggressive” while only 24% of white patients did. For AA patients, cost, treatment time, and recovery time were considered very important more than white patients.
AHRQ-funded.
Citation: Gordon BE, Basak R, Carpenter WR .
Factors influencing prostate cancer treatment decisions for African American and white men.
Cancer 2019 May 15;125(10):1693-700. doi: 10.1002/cncr.31932..
Keywords: Decision Making, Cancer, Cancer: Prostate Cancer, Disparities, Men's Health, Outcomes, Patient-Centered Outcomes Research, Racial and Ethnic Minorities
Crawford ED, Koo PJ, Shore N
A clinician's guide to next generation imaging in patients with advanced prostate cancer (RADAR III).
This paper reports on the convening of the Radiographic Assessments for Detection of Advanced Recurrence (RADAR III) Group to offer guidance on the use of next generation imaging to stage prostate cancer based on available data and clinical experience. The RADAR III Group recommends next generation imaging techniques in select patients in whom disease progression is suspected based on biomarker values, comorbidities and symptoms.
AHRQ-funded.
Citation: Crawford ED, Koo PJ, Shore N .
A clinician's guide to next generation imaging in patients with advanced prostate cancer (RADAR III).
J Urol 2019 Apr;201(4):682-92. doi: 10.1016/j.juro.2018.05.164..
Keywords: Men's Health, Cancer: Prostate Cancer, Cancer, Diagnostic Safety and Quality, Imaging, Evidence-Based Practice, Guidelines
Schmidt B, Eapen RS, Cowan JE
Practice patterns of primary EBRT with and without ADT in prostate cancer treatment.
This study investigated usage of external-beam radiation therapy (EBRT), with or without neoadjuvant androgen deprivation therapy (ADT), using data from a community-based prospective disease registry (CaPSURE). Data on 1337 men diagnosed between 1990 and 2014 with localized disease who received EBRT as primary treatment was compared. The authors conclude that use of ADT in conjunction with primary EBRT has increased in frequency and duration since 1990, and that men who received ADT have higher risk characteristics than those who receive EBRT alone.
AHRQ-funded; HS019356.
Citation: Schmidt B, Eapen RS, Cowan JE .
Practice patterns of primary EBRT with and without ADT in prostate cancer treatment.
Prostate Cancer Prostatic Dis 2019 Mar;22(1):117-24. doi: 10.1038/s41391-018-0084-3..
Keywords: Cancer: Prostate Cancer, Cancer, Patient-Centered Outcomes Research, Practice Patterns, Evidence-Based Practice, Comparative Effectiveness, Outcomes, Treatments
Elstad EA, Sheridan SL, Lee JG
Have screening harms become newsworthy? News coverage of prostate and colorectal cancer screening since the 2008 USPSTF recommendation changes.
The researchers aimed to determine whether newspapers portrayed screening for prostate and colorectal cancers differently after the 2008 USPSTF recommendation changes. In US newspapers from 2005 to 2012, they found that benefits in prostate cancer screening articles and harms and benefits in colonoscopy articles did not change over time, but mentions of prostate cancer screening harms increased after 2008. They concluded that consumers, especially lay consumers, are receiving unbalanced information on cancer screening.
AHRQ-funded; HS021133; HS000032.
Citation: Elstad EA, Sheridan SL, Lee JG .
Have screening harms become newsworthy? News coverage of prostate and colorectal cancer screening since the 2008 USPSTF recommendation changes.
J Behav Med 2014 Dec;37(6):1242-51. doi: 10.1007/s10865-014-9572-7.
.
.
Keywords: Cancer: Colorectal Cancer, Colonoscopy, Cancer: Prostate Cancer, Screening, U.S. Preventive Services Task Force (USPSTF)
Bhavsar NA, Bream JH, Meeker AK
A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II.
The authors evaluated the association between peripheral-cytokine concentrations and prostate cancer. They found that men with a prediagnostic circulating TH1 profile and higher IL6 may have a lower risk of prostate cancer, including aggressive disease. They concluded that identifying specific inflammatory cytokines associated with prostate cancer may lead to improved prevention and treatment strategies.
AHRQ-funded; HS019488.
Citation: Bhavsar NA, Bream JH, Meeker AK .
A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II.
Cancer Epidemiol Biomarkers Prev 2014 Nov;23(11):2561-7. doi: 10.1158/1055-9965.epi-14-0010.
.
.
Keywords: Patient-Centered Outcomes Research, Cancer: Prostate Cancer, Risk
Rabin BA, Ellis JL, Steiner JF
Health-care utilization by prognosis profile in a managed care setting: using the Surveillance, Epidemiology and End Results Cancer Survival Calculator SEER*CSC.
The authors described health service utilization patterns of subgroups of prostate cancer and colorectal cancer (CRC) patients with different relative probabilities of dying of their cancer or other conditions. They found that although a new diagnosis of cancer increased utilization of cancer-related services for an extended time period, the timing of cancer diagnosis did not appear to affect other types of utilization.
AHRQ-funded; HS019520.
Citation: Rabin BA, Ellis JL, Steiner JF .
Health-care utilization by prognosis profile in a managed care setting: using the Surveillance, Epidemiology and End Results Cancer Survival Calculator SEER*CSC.
J Natl Cancer Inst Monogr 2014 Nov;2014(49):275-81. doi: 10.1093/jncimonographs/lgu023.
.
.
Keywords: Cancer: Prostate Cancer, Cancer: Colorectal Cancer, Cancer, Healthcare Utilization, Mortality, Healthcare Delivery
Feuer EJ, Rabin BA, Zou Z
The Surveillance, Epidemiology, and End Results Cancer Survival Calculator SEER*CSC: validation in a managed care setting.
The researchers externally validate the nomograms for prostate and colorectal cancer using data from Kaiser Permanente Colorado. Their results indicated that the colorectal and prostate cancer nomograms are reliable tools for physicians and patients to use to obtain information on prognosis and assist in establishing priorities for both treatment of the cancer and other conditions, particularly when a patient is elderly and/or has significant comorbidities.
AHRQ-funded; HS019520.
Citation: Feuer EJ, Rabin BA, Zou Z .
The Surveillance, Epidemiology, and End Results Cancer Survival Calculator SEER*CSC: validation in a managed care setting.
J Natl Cancer Inst Monogr 2014 Nov;2014(49):265-74. doi: 10.1093/jncimonographs/lgu021.
.
.
Keywords: Cancer: Colorectal Cancer, Cancer: Prostate Cancer, Cancer, Mortality
Merdan S, Womble PR, Miller DC
Toward better use of bone scans among men with early-stage prostate cancer.
This study evaluated the performance of published guidelines compared with that of current practice for radiographic staging of men with newly diagnosed prostate cancer. It found that, based on current practice patterns, more uniform application of existing guidelines would ensure that bone scans are performed for almost all men with bone metastases, while avoiding many negative imaging studies.
AHRQ-funded; HS018346
Citation: Merdan S, Womble PR, Miller DC .
Toward better use of bone scans among men with early-stage prostate cancer.
Urology. 2014 Oct;84(4):793-8. doi: 10.1016/j.urology.2014.06.010..
Keywords: Cancer: Prostate Cancer, Guidelines, Imaging
Goodwin JS, Jaramillo E, Yang L
Is anyone listening? Variation in PSA screening among providers for men 75+ before and after United States Preventive Services Task Force recommendations against it: a retrospective cohort study.
The authors assessed prostate specific antigen (PSA) screening by primary care physicians (PCPs) before and after the 2008 United States Preventive Services Task Force (USPSTF) recommendations. They found that the USPSTF recommendation did not increase consensus among PCPs regarding PSA screening of older men.
AHRQ-funded; HS022134.
Citation: Goodwin JS, Jaramillo E, Yang L .
Is anyone listening? Variation in PSA screening among providers for men 75+ before and after United States Preventive Services Task Force recommendations against it: a retrospective cohort study.
PLoS One 2014 Sep 10;9(9):e107352. doi: 10.1371/journal.pone.0107352.
.
.
Keywords: Cancer: Prostate Cancer, Practice Patterns, Primary Care, Screening, U.S. Preventive Services Task Force (USPSTF)
Cobran EK, Wutoh AK, Lee E
Perceptions of prostate cancer fatalism and screening behavior between United States-born and Caribbean-born Black males.
The purpose of this study was to compare perceptions of prostate cancer (CaP) fatalism and predictors of CaP screening with Prostate Specific Antigen (PSA) testing between U.S.-born and Caribbean-born African-American males. In their study of 211 U.S.-born and Caribbean-born Black males between ages 39–75, the researchers found that nativity was not a significant predictor of CaP screening with PSA testing within the last year.
AHRQ-funded; HS011673.
Citation: Cobran EK, Wutoh AK, Lee E .
Perceptions of prostate cancer fatalism and screening behavior between United States-born and Caribbean-born Black males.
J Immigr Minor Health 2014 Jun;16(3):394-400. doi: 10.1007/s10903-013-9825-5..
Keywords: Cancer: Prostate Cancer, Screening, Racial and Ethnic Minorities, Racial and Ethnic Minorities, Cancer
Barbash GI, Friedman B, Glied SA
AHRQ Author: Barbash GI, Friedman B, Glied SA, Steiner CA
Factors associated with adoption of robotic surgical technology in US hospitals and relationship to radical prostatectomy procedure volume.
The authors aimed to identify the factors associated with hospitals' decisions to adopt robotic technology and the consequences of these decisions. They found that hospitals in areas where a higher proportion of other hospitals had already acquired a robot were more likely to acquire one, as were those with more than 300 beds and teaching hospitals. They also found a significant association between years with a robot and the change in the number of radical prostatectomies. They concluded that local area robot competition was associated with the rapid spread of robot technology in the United States.
AHRQ-authored.
Citation: Barbash GI, Friedman B, Glied SA .
Factors associated with adoption of robotic surgical technology in US hospitals and relationship to radical prostatectomy procedure volume.
Ann Surg 2014 Jan;259(1):1-6. doi: 10.1097/SLA.0b013e3182a5c8b8.
.
.
Keywords: Hospitals, Cancer: Prostate Cancer, Surgery